Wolfgang Fendler, MD, discusses the utility and pending FDA approval of 68Ga-PSMA-11 PET in prostate cancer.
Wolfgang Fendler, MD
Advertisement
Articles by Wolfgang Fendler, MD
Wolfgang Fendler, MD, discusses the rationale for creating the 68Ga-PSMA-11 PET in prostate cancer.
Wolfgang Fendler, MD, discusses the impact of 68Ga-PSMA-11 PET imaging on the clinical management of patients with prostate cancer.
Wolfgang Fendler, MD, discusses the utility of 68Ga-PSMA-11 PET in prostate cancer.
Wolfgang Fendler, MD, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, discusses the clinical need for 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer.
Advertisement
Latest Updated Articles
Dr. Fendler on Clinical Need for 68GA-PSMA-11 PET in Prostate CancerPublished: February 21st 2020 | Updated:
Dr. Fendler on the Utility of 68Ga-PSMA-11 PET in Prostate CancerPublished: March 17th 2020 | Updated:
- Dr. Fendler on the Impact of 68Ga-PSMA-11 PET Imaging on Prostate Cancer Management
Published: March 18th 2020 | Updated:
Dr. Fendler on Rationale for Creating the 68Ga-PSMA-11 PET in Prostate CancerPublished: April 4th 2020 | Updated:
Dr. Fendler on Impact of 68Ga-PSMA-11 PET on Prostate Cancer ManagementPublished: April 29th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5